A novel cyclosporine binding assay.

Area of Science:

• Immunology
• Pharmacology
• Cell Biology

Background:

• Cyclosporine A (CsA) is an immunosuppressive drug with a complex mechanism of action.
• Understanding CsA's cellular targets is crucial for optimizing its therapeutic use and minimizing side effects.

Purpose of the Study:

• To characterize the specific binding sites for [3H]cyclosporine A (CsA) in BALB/c mouse spleen cells.
• To determine the affinity (KD) and density (Bmax) of these CsA binding sites.
• To investigate the presence of CsA binding sites in various cell types.

Main Methods:

• A novel centrifugation assay was developed to rapidly separate bound from free [3H]CsA.
• Equilibrium and kinetic binding studies were performed using varying concentrations of [3H]CsA.
• Scatchard analysis was employed to analyze binding data.
• Binding was assessed in BALB/c mouse spleen cells, liposomes, WEHI-5 B-lymphoma cells, N1E-115 neuroblastoma cells, and A204 rhabdosarcoma cells.

Main Results:

• A single class of specific, saturable CsA binding sites was observed under equilibrium conditions (KD = 95 nM, Bmax = 2.4 million sites/cell).
• Kinetic studies revealed two distinct binding sites with KD values of 290 nM and 9.6 µM.
• [3H]CsA exhibited only nonspecific binding to phosphatidylcholine:cholesterol liposomes.
• Specific CsA binding sites were detected in murine B-lymphoma, neuroblastoma, and human rhabdosarcoma cells.

Conclusions:

• BALB/c mouse spleen cells possess at least two distinct non-lipid CsA binding sites.
• CsA binding sites are present in both lymphoid and nonlymphoid cell types.
• The characterized binding sites may play a role in CsA's pharmacological effects.